{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:33:26Z","timestamp":1738388006006,"version":"3.35.0"},"reference-count":69,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,2,1]]},"DOI":"10.2169\/internalmedicine.3478-24","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:12:21Z","timestamp":1720044741000},"page":"409-422","source":"Crossref","is-referenced-by-count":0,"title":["Metastatic Pleomorphic Carcinoma of the Lung with Extensive Chromosomal Rearrangements: An Autopsy Case with a Literature Review"],"prefix":"10.2169","volume":"64","author":[{"given":"Fukuko","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Division of General Medicine, Department of Comprehensive Medicine 1, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Matsuzawa Adachi","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Department of Comprehensive Medicine 1, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Department of Comprehensive Medicine 1, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Department of Comprehensive Medicine 1, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shiihara","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Comprehensive Medicine 1, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Fukuchi","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Department of Comprehensive Medicine 1, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Hiruta","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Tanno","sequence":"additional","affiliation":[{"name":"Department of Radiology, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Oyama-Manabe","sequence":"additional","affiliation":[{"name":"Department of Radiology, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Oshiro","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Department of Comprehensive Medicine 1, Jichi Medical University, Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological Typing of Lung and Pleural Tumours 3rd ed. New York. Springer, 1999.","DOI":"10.1007\/978-3-642-60049-4"},{"key":"2","unstructured":"2. Rossi G, Boland J, Pelosi G, Roden A. Pleomorphic carcinoma of the lung. In: World Health Organ Classification of Tumours Editorial Board. 5th ed. Thoracic Tumours. International Agency for Research on Cancer, Lyon, 2021: 103-105."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chen F, Sonobe M, Sato T, et al. Clinicopathological characteristics of surgically resected pulmonary pleomorphic carcinoma. Eur J Cardiothorac Surg 41: 1037-1042, 2012.","DOI":"10.1093\/ejcts\/ezr136"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chen Z, Liu J, Min L. Clinicopathological characteristics, survival outcomes and prognostic factors in pleomorphic carcinoma: a SEER population-based study. BMC Pulm Med 22: 116, 2022.","DOI":"10.1186\/s12890-022-01915-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nagano M, Kohsaka S, Hayashi T, et al. Comprehensive molecular profiling of pulmonary pleomorphic carcinoma. NPJ Precis Oncol 5: 57, 2021.","DOI":"10.1038\/s41698-021-00201-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kim S, Kim MY, Koh J, et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas. Eur J Cancer 51: 2698-2707, 2015.","DOI":"10.1016\/j.ejca.2015.08.013"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Imanishi N, Hirai A, Yoneda K, et al. Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung. J Surg Oncol 117: 1563-1569, 2018.","DOI":"10.1002\/jso.25041"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lee J, Choi YL, Jung HA, et al. Outstanding clinical efficacy of PD-1\/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. Eur J Cancer 132: 150-158, 2020.","DOI":"10.1016\/j.ejca.2020.03.029"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chang YL, Wu CT, Shih JY, Lee YC. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Ann Surg Oncol 18: 2952-2960, 2011.","DOI":"10.1245\/s10434-011-1621-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kano Y, Kataoka N, Kunimatsu Y, et al. Pulmonary pleomorphic carcinoma harboring EGFR mutation successfully treated with osimertinib: a case report. Medicina (Kaunas) 58: 2022.","DOI":"10.3390\/medicina58060706"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Herndon J, Nadeau AM, Davidge-Pitts CJ, Young WF, Bancos I. Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine 62: 721-728, 2018.","DOI":"10.1007\/s12020-018-1737-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mohammad K, Sadikot RT. Adrenal insufficiency as a presenting manifestation of nonsmall-cell lung cancer. South Med J 102: 665-667, 2009.","DOI":"10.1097\/SMJ.0b013e3181a56042"},{"key":"13","unstructured":"13. Singh N, Madan K, Aggarwal AN, Das A. Symptomatic large bilateral adrenal metastases at presentation in small-cell lung cancer: a case report and review of the literature. J Thorac Dis 5: E83-E86, 2013."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Karanikiotis C, Tentes AA, Markakidis S, Vafiadis K. Large bilateral adrenal metastases in non-small-cell lung cancer. World J Surg Oncol 2: 37, 2004.","DOI":"10.1186\/1477-7819-2-37"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Taira N, Kawabata T, Ichi T, et al. A case of synchronous double primary lung cancer presenting with pleomorphic carcinoma and adenocarcinoma. Am J Case Rep 15: 576-579, 2014.","DOI":"10.12659\/AJCR.892339"},{"key":"16","unstructured":"16. Segawa M, Kusajima Y, Saito K. [Pleomorphic carcinoma of the lung rapidly developed multiple metastases after surgery]. Kyobu Geka (Jpn J Thorac Surg) 59: 387-391, 2006."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hayashi K, Tokui K, Inomata M, et al. Case series of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. In Vivo 35: 1687-1692, 2021.","DOI":"10.21873\/invivo.12428"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tokuyasu H, Ishikawa S, Sakai H, Ikeuchi T, Miura H. Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. Respir Med Case Rep 28: 100879, 2019.","DOI":"10.1016\/j.rmcr.2019.100879"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Matsumoto Y, Miura T, Horiuchi H, Usui K. The successful treatment of pulmonary pleomorphic carcinoma with pembrolizumab: a case report. Case Rep Oncol 10: 752-757, 2017.","DOI":"10.1159\/000479552"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chang HC, Hsu CL, Chang YL, Yu CJ. Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy. Respirol Case Rep 8: e0597, 2020.","DOI":"10.1002\/rcr2.597"},{"key":"21","unstructured":"21. Etori S, Kenmotsu Y, Nakagawa K, et al. [A case of pulmonary pleomorphic carcinoma in a hemodialysis patient treated with pembrolizumab]. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 49: 879-881, 2022."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chen Y, Zhang H, Shi J, Wang T. A partial response of pulmonary pleomorphic carcinoma to camrelizumab (PD1 monoclonal antibody) monotherapy: a case report. Onco Targets Ther 13: 12471-12476, 2020.","DOI":"10.2147\/OTT.S279004"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Ikematsu Y, Yoneshima Y, Ijichi K, et al. Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. Lung Cancer 112: 230-231, 2017.","DOI":"10.1016\/j.lungcan.2017.07.020"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Oguri T, Sasada S, Seki S, et al. A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation. Respir Med Case Rep 33: 101405, 2021.","DOI":"10.1016\/j.rmcr.2021.101405"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yvorel V, Patoir A, Casteillo F, et al. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. PLOS ONE 12: e0180346, 2017.","DOI":"10.1371\/journal.pone.0180346"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Naito M, Tamiya A, Takeda M, et al. A high PD-L1 expression in pulmonary pleomorphic carcinoma correlates with parietal-pleural invasion and might predict a poor prognosis. Intern Med 58: 921-927, 2019.","DOI":"10.2169\/internalmedicine.1462-18"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Shijubou N, Asai Y, Hosaka M, et al. Metastatic pulmonary pleomorphic carcinoma replaced by a granulomatous lesion after spontaneous regression and PD-1 blockade-induced regression: can epithelioid granuloma be a histological hallmark of cancer immunity? Immunol Med 46: 93-96, 2023.","DOI":"10.1080\/25785826.2023.2193283"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ken O, Akira S, Hideki M, et al. Clinical course of surgically treated pleomorphic carcinoma of the lung. Jpn J Lung Cancer 57: 8-11, 2017.","DOI":"10.2482\/haigan.57.8"},{"key":"29","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1186\/s12885-022-10176-4","volume":"22","author":"K Kojima","year":"2022","unstructured":"29. Kojima K, Imai S, Samejima H, et al. PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study. BMC Cancer 22: 1066, 2022.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kaira K, Horie Y, Ayabe E, et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 5: 460-465, 2010.","DOI":"10.1097\/JTO.0b013e3181ce3e3c"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Chang YL, Yang CY, Lin MW, Wu CT, Yang PC. High co-expression of PD-L1 and HIF-1\u03b1 correlates with tumour necrosis in pulmonary pleomorphic carcinoma. Eur J Cancer 60: 125-135, 2016.","DOI":"10.1016\/j.ejca.2016.03.012"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol 39: 267-270, 2009.","DOI":"10.1093\/jjco\/hyn155"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Saitoh M, Niijima M, Takiguchi Y, et al. An early event of EGFR mutation in pleomorphic carcinoma of the lung. Int J Clin Oncol 16: 770-773, 2011.","DOI":"10.1007\/s10147-011-0247-x"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Petersen I, Kotb WF, Friedrich KH, Schl\u00fcns K, B\u00f6cking A, Dietel M. Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. Lung Cancer 65: 312-318, 2009.","DOI":"10.1016\/j.lungcan.2008.12.013"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Pelosi G, Gasparini P, Cavazza A, et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer 77: 507-514, 2012.","DOI":"10.1016\/j.lungcan.2012.05.093"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Li X, Wang D, Zhao Q, et al. Clinical significance and next-generation sequencing of Chinese pulmonary sarcomatoid carcinoma. Sci Rep 7: 3947, 2017.","DOI":"10.1038\/s41598-017-04296-2"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Manabe S, Kasajima R, Murakami S, et al. Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique. Thorac Cancer 11: 2262-2269, 2020.","DOI":"10.1111\/1759-7714.13536"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Yang Z, Xu J, Li L, et al. Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nat Commun 11: 4878, 2020.","DOI":"10.1038\/s41467-020-18702-3"},{"key":"39","unstructured":"39. Han F, Osmani M, Jaronczyk M, Kang Y. Metastatic pulmonary pleomorphic carcinoma involving the jejunum: a case report and review of the literature. Int J Clin Exp Pathol 16: 133-137, 2023."},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Luo Y, Wei J, Zhang J, Zeng L, Zeng Z, Liu A. Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib. Lung Cancer 155: 170-174, 2021.","DOI":"10.1016\/j.lungcan.2021.03.019"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Mukai Y, Ueno H. Establishment and implementation of cancer genomic medicine in Japan. Cancer Sci 112: 970-977, 2021.","DOI":"10.1111\/cas.14754"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Kunimasa K, Inoue T, Matsueda K, et al. Cytokine release syndrome and immune-related pneumonitis associated with tumor progression in a pulmonary pleomorphic carcinoma treated with nivolumab plus ipilimumab treatment: a case report. JTO Clin Res Rep 3: 100272, 2022.","DOI":"10.1016\/j.jtocrr.2021.100272"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Kodama K, Maniwa T, Kimura Y, et al. Concurrent combination of irradiation and immune checkpoint inhibitor for recurrent pleomorphic carcinoma of the lung. Int Cancer Conf J 7: 43-47, 2018.","DOI":"10.1007\/s13691-017-0315-9"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44. Gounant V, Brosseau S, Naltet C, et al. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer 99: 162-165, 2016.","DOI":"10.1016\/j.lungcan.2016.07.010"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Ito K, Hataji O, Katsuta K, et al.  "Pseudoprogression" of pulmonary pleomorphic carcinoma during nivolumab therapy. J Thorac Oncol 11: e117-e119, 2016.","DOI":"10.1016\/j.jtho.2016.05.002"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Kanazu M, Uenami T, Yano Y, et al. Case series of pleomorphic carcinomas of the lung treated with nivolumab. Thorac Cancer 8: 724-728, 2017.","DOI":"10.1111\/1759-7714.12505"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Marchand L, Paulus V, Fabien N, et al. Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol 12: e182-e184, 2017.","DOI":"10.1016\/j.jtho.2017.07.021"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Fujimoto E, Yokoi T, Mikami K, et al. Successful treatment of pulmonary pleomorphic carcinoma with nivolumab: a case report. Case Rep Oncol 11: 336-340, 2018.","DOI":"10.1159\/000489392"},{"key":"49","unstructured":"49. Kawamata O, Murata T, Uda M. [Pulmonary pleomorphic carcinoma relapsed after surgery surviving long-term by chemotherapy and nivolumab]. Kyobu Geka (Jpn J Thorac Surg) 71: 329-333, 2018."},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Matsuoka H, Kimura H, Koba H, et al. Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer 19: e597-e599, 2018.","DOI":"10.1016\/j.cllc.2018.04.009"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Okamura K, Fukuda Y, Soda H, et al. Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab. Thorac Cancer 9: 193-196, 2018.","DOI":"10.1111\/1759-7714.12557"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Tozuka T, Sugano T, Noro R, et al. Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. Oxf Med Case Rep 2018: omy094, 2018.","DOI":"10.1093\/omcr\/omy094"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Yoshimura A, Takumi C, Tsuji T, et al. Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: a case report. Clin Case Rep 6: 1338-1341, 2018.","DOI":"10.1002\/ccr3.1627"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Honjo O, Kubo T, Sugaya F, et al. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer 7: 97, 2019.","DOI":"10.1186\/s40425-019-0582-4"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Ota T, Niho S, Kirita K, Ishii G, Tsuboi M, Goto K. Impressive response to nivolumab of non-small-cell lung cancer containing sarcomatoid components. Respirol Case Rep 7: e00477, 2019.","DOI":"10.1002\/rcr2.477"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Senoo S, Ninomiya T, Makimoto G, et al. Rapid and long-term response of pulmonary pleomorphic carcinoma to nivolumab. Intern Med 58: 985-989, 2019.","DOI":"10.2169\/internalmedicine.0890-18"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Yaguchi D, Ichikawa M, Ito M, Okamoto S, Kimura H, Watanabe K. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence. Thorac Cancer 10: 1263-1266, 2019.","DOI":"10.1111\/1759-7714.13029"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Okauchi S, Sasatani Y, Shiozawa T, et al. Combination of pembrolizumab with platinum-containing chemotherapy for pleomorphic carcinoma of the lung. In Vivo 34: 1439-1443, 2020.","DOI":"10.21873\/invivo.11926"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Yorozuya T, Taya T, Yasuda K, et al. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: a case report. Thorac Cancer 11: 1090-1093, 2020.","DOI":"10.1111\/1759-7714.13331"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Kojima Y, Takeyabu K, Kimura M, et al. Case report: postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab. Respir Med Case Rep 34: 101501, 2021.","DOI":"10.1016\/j.rmcr.2021.101501"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Kuge T, Okabe F, Yamamoto Y, et al. Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: a case report. Thorac Cancer 12: 1935-1939, 2021.","DOI":"10.1111\/1759-7714.13948"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Matsuda M, Kai Y, Harada S, Suzuki K, Hontsu S, Muro S. Duodenal metastasis of pulmonary pleomorphic carcinoma: a case report. Case Rep Oncol 14: 1511-1515, 2021.","DOI":"10.1159\/000519664"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Shimamura S, Saiki M, Ide S, et al. Significant therapeutic effectiveness of durvalumab after chemoradiotherapy for a patient with post-operative recurrent pulmonary pleomorphic carcinoma. Respirol Case Rep 9: e00781, 2021.","DOI":"10.1002\/rcr2.781"},{"key":"64","unstructured":"64. Yamaki M, Noriyuki T, Yonehara S. [Effectiveness of pembrolizumab for pulmonary pleomorphic carcinoma with pleural dissemination and gingival metastasis]. Kyobu Geka (Jpn J Thorac Surg) 74: 910-914, 2021."},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Yamasaki M, Matsumoto Y, Nakamoto K, Hattori N. Pulmonary pleomorphic carcinoma in an elderly patient treated with pembrolizumab shows a marked response. J Cancer Res Ther 17: 1580-1582, 2021.","DOI":"10.4103\/jcrt.JCRT_361_19"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Ikushima H, Asaga R, Sakatani T, Masuda Y, Morikawa T, Usui K. Successful control of intestinal bleeding from metastasis of pulmonary pleomorphic carcinoma with pembrolizumab: a case report. Medicine (Baltimore) 101: e31220, 2022.","DOI":"10.1097\/MD.0000000000031220"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Murao K, Mori Y, Takahashi Y, et al. Simultaneous pseudoprogression and an immune-related adverse event of pulmonary pleomorphic carcinoma after combined therapy with cytotoxic anticancer agents and immune checkpoint inhibitor. Intern Med 61: 3259-3264, 2022.","DOI":"10.2169\/internalmedicine.8916-21"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Sako M, Nokihara H, Kondo K, et al. A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab. Thorac Cancer 13: 129-132, 2022.","DOI":"10.1111\/1759-7714.14243"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Jiang T, Wang H, Xue F, et al. Pulmonary pleomorphic carcinoma treated with PD-1 inhibitor: two case reports. Thorac Cancer 14: 3240-3244, 2023.","DOI":"10.1111\/1759-7714.15120"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/3\/64_3478-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:34:22Z","timestamp":1738380862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/3\/64_3478-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3478-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"article-number":"3478-24"}}